Jaffer A. Ajani, MD / Ian Chau, MD, FRCP - Gaining New Ground With Immunotherapy in the Management of Early and Advanced Gastrointestinal Cancers: Translating Progress Into Clinical Practice in Gastric, Esophageal, GEJ, and Colorectal Cancers

Go online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding the biomarker-guided use of immune checkpoint inhibitors, including via testing for PD-L1, MMR/MSI status, TMB, and other molecular features, in appropriate patients with advanced GI cancers, Evaluate the most recent clinical trial data on validated dual- and single-agent immune checkpoint inhibitor strategies for patients with advanced GI cancers, Summarize emerging evidence and current guideline recommendations on the use of immune checkpoint inhibitors as part of novel combination regimens and in earlier disease, including first-line and perioperative settings, for patients with GI cancers, Apply recent evidence and guideline recommendations on the use of immune checkpoint inhibitors to the management of patients with early- to advanced-stage GI cancers, including the option of clinical trial participation when appropriate.